Pfizer To Monitor Off-Label Drug Use Under Neurontin Settlement
Executive Summary
Pfizer will provide periodic reports to the HHS Inspector General about off-label use trends for its products under the May 13 settlement of an investigation into the company's promotion of Neurontin
You may also be interested in...
Neurontin Liability Suits Take Personal Twist With Witness Intimidation Charge
When you hear about witness intimidation in a drug case, you usually don't think an Rx kingpin is involved. But Pfizer's use of a private detective in the first Neurontin liability case to go to trial has produced a behind-the-scenes drama that could spill over into subsequent litigation
Neurontin Liability Suits Take Personal Twist With Witness Intimidation Charge
When you hear about witness intimidation in a drug case, you usually don't think an Rx kingpin is involved. But Pfizer's use of a private detective in the first Neurontin liability case to go to trial has produced a behind-the-scenes drama that could spill over into subsequent litigation
Pfizer Selzentry Will Launch At $29/Day; sNDA For Full Approval Slated For August
Pfizer's HIV therapy Selzentry (maraviroc) will be available in pharmacies by mid-September following FDA's Aug. 6 approval of the first-in-class CCR5 co-receptor antagonist